Endogenous GLP-1 regulates postprandial glycemia in humans: Relative contributions of insulin, glucagon, and gastric emptying

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 1, 2011, Pages 229-236

  Nicolaus, Mathias ^a   Brödl, Julia ^a   Linke, Rainer ^b   Woerle, Hans Juergen ^a   Göke, Burkhard ^a   Schirra, Jörg ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN(9-39)AMIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BAROSTAT; COLLOID; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; MANOMETRY; NORMAL HUMAN; OAT; PRIORITY JOURNAL; SCINTIGRAPHY; STOMACH EMPTYING; STOMACH MOTILITY;

EID: 78650860373     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0841     Document Type: Article

References (32)

1. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498 (Pubitemid 16035703)
2. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA 1996 Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586 (Pubitemid 26181104)
3. Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Göke B, Katschinski M 1998 Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 156:177-186
4. Schirra J, Houck P,Wank U, Arnold R, Göke B, Katschinski M 2000 Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46:622-631
5. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M 1998 Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421-1430
6. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B 2006 Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55:243-251 (Pubitemid 43117285)
7. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Göke B 2009 GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 21:609-618
8. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR 1999 Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86-93
9. Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M,Gerich J, Goke B, Schirra J 2008 Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab 294:E103-E109
10. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK, Horowitz M 2010 Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95:215-221
11. Salehi M, Vahl TP, D'Alessio DA 2008 Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 93:4909-4916
12. Moragas G, Azpiroz F, Pavia J, Malagelada JR 1993 Relations among intragastric pressure, postcibal perception, and gastric emptying. Am J Physiol 264(6 Pt 1):G1112-G1117
13. Katschinski M, Dahmen G, Reinshagen M, Beglinger C, Koop H, Nustede R, Adler G 1992 Cephalic stimulation of gastrointestinal secretory and motor responses in humans. Gastroenterology 103:383-391
14. Linke R, Muenzing W, Hahn K, Tatsch K 2000 Evaluation of gastric motility by Fourier analysis of condensed images. Eur J Nucl Med 27:1531-1537
15. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ 1995 Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630
16. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA 2003 Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725
17. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273(5 Pt 1):E981-E988
18. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332
19. Wishart JM, Horowitz M, Morris HA, Jones KL, Nauck MA 1998 Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 19:1049-1053
20. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW 1993 Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36:857-862
21. Kolligs F, Fehmann HC, Göke R, Göke B 1995 Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19
22. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR 1995 Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417-421
23. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M 2007 Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetes. Diabetes 56:1475-1480
24. Schirra J, Morper M, Nicolaus M, Woerle HJ, Göke B 2008 The efficacy of exendin(9-39)amide as a GLP-1 receptor antagonist in human. Gut 57(Suppl II), A85
25. Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C 1997 Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 113:60-66
26. Desai KM, Sessa WC, Vane JR 1991 Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 351:477-479
27. Paterson CA, Anvari M, Tougas G, Huizinga JD 2000 Nitrergic and cholinergic vagal pathways involved in the regulation of canine proximal gastric tone: an in vivo study. Neurogastroenterol Motil 12:301-306
28. Ropert A, des Varannes SB, Bizais Y, Rozé C, Galmiche JP 1993 Simultaneous assessment of liquid emptying and proximal gastric tone in humans. Gastroenterology 105:667-674
29. de Heer J, Rasmussen C, Coy DH, Holst JJ 2008 Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263-2270
30. Fehmann HC, Hering BJ, Wolf MJ, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, Göke B 1995 The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196-200
31. Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, Melvin DL, Egan JM 2009 Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58:1342-1349
32. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ 2010 The glucagonostatic and insulinotropic effects of glucagon-like peptide-1 contribute equally to its glucose-lowering action. Diabetes 59:1765-1770